Newsletter Volume 37, Number 1, 2022
Introduction
I would like to wish you a Happy New Year, although it is a little late. It has been almost two full years since the spread of the new coronavirus (Covid-19) began, and the year 2022 has also begun with the rapid spread of a new mutant strain (Omicron strain). I am sure that everyone is working hard in a new environment every day, with no end in sight. It has become commonplace for people around me to work not only by telecommuting several times a week, but also by conducting experiments in the morning and organizing and analyzing data, preparing materials for meetings, participating in meetings, etc. in the afternoon. This “New Normal” of working both onsite and online will continue even after the Corona Disaster is over, but I hope that by maximizing the benefits of both, we will be able to work more efficiently and use our time more freely to come up with new ideas. I hope to make the most of the merits of both sides of the business, so that I can use my time to generate ideas more freely. Having said that, I sincerely hope that at this year’s annual meeting in Yokohama, we will be able to discuss directly with you face to face for the first time in a while….
By the way…have you made your New Year’s resolutions? I have decided to restart E. Guitar, which I have neglected for a long time. It is always exciting to learn something new. It’s always exciting to work on something new, and it’s not always going to go as smoothly as you’d like, but if you think about it, it’s the same with pharmaceutical research and development (or much harder, I suppose…). This time around, I hope to continue to enjoy my work without giving up.
Pharmacokinetics is also developing day by day toward the creation of new knowledge, taking in various innovative technologies and scientific developments in recent years. In order to serve as a starting point, we would like to make this newsletter a forum for disseminating information on the latest findings in pharmacokinetics and the state-of-the-art science in related fields. Your continued support and cooperation will be greatly appreciated. (Y.N.)
Introduction of Feature Articles
Topics
With the development of new discoveries and methods, the evaluation items and methods of pharmaceuticals from research and development to post-marketing evaluation are constantly evolving. Correspondingly, regulatory information from regulatory authorities in Japan, the U.S., and Europe, as well as ICH and other regulatory bodies, is constantly updated. Here, we will introduce the latest technologies and findings used in drug development, regulatory information on drug review, and related information topics. We hope that you will find this article useful for your work.